This is a new approach in genetic engineering focused on overcoming acute Graft versus Host Disease (aGVHD) in gene-modified immune effector cells. By using micro RNA155 (miR155) as the integration site for CAR-T cells, this technology aims to enhance the functionality and specificity of immune cells. It involves the integration of DNA encoding CARs into the miR155 gene locus using Cas9/RNP+AAV, resulting in simultaneous gene knockout and CAR knock-in with high efficiency. This universal construct, facilitating the insertion of any transgene into human primary T cells, is a breakthrough in cell therapy. The IP has potential applications in various blood cancers, offering dual specificity and enhanced function of CAR-T cells. The development team plans to further characterize the functionality of MIR155 KO-CD33CAR-T cells through in vitro and in vivo studies.